# Correction: Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1

**Authors:** Warren Fiskus, Christopher P. Mill, Christine Birdwell, John A. Davis, Kaberi Das, Steffen Boettcher, Tapan M. Kadia, Courtney D. DiNardo, Koichi Takahashi, Sanam Loghavi, Michael J. Soth, Tim Heffernan, Gerard M. McGeehan, Xinjia Ruan, Xiaoping Su, Christopher R. Vakoc, Naval Daver, Kapil N. Bhalla

PMC · DOI: 10.1038/s41408-025-01306-9 · Blood Cancer Journal · 2025-05-21

## Full-text entities

- **Genes:** KMT2A (lysine methyltransferase 2A) [NCBI Gene 4297] {aka ALL-1, ALL1, CXXC7, GAS7, HRX, HTRX}, NPM1 (nucleophosmin 1) [NCBI Gene 4869] {aka B23, NPM}, MEN1 (menin 1) [NCBI Gene 4221] {aka MEAI, SCG2}
- **Diseases:** AML (MESH:D015470)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12095577/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12095577/full.md

---
Source: https://tomesphere.com/paper/PMC12095577